Concepedia

Ganesh Mugundu

GM

Statistics

Publications

32

Citations

1K

H-Index

19

Active since

2008

Affiliations

AstraZeneca (United States)(Current)

AstraZeneca (United Kingdom)

Tennessee Oncology

Sarah Cannon

Pfizer (United States)

Ganesh Mugundu is an author at AstraZeneca (United States) specializing in medicine, pharmacology, and pharmacotherapy.

ORCID

Top concepts

Publications per year

2008–2023

32

Publications

32

Intestinal Human Colon Adenocarcinoma Cell Line LS180 Is an Excellent Model to Study Pregnane X Receptor, but Not Constitutive Androstane Receptor, Mediated CYP3A4 and Multidrug Resistance Transporter 1 Induction: Studies with Anti-Human Immunodeficiency Virus Protease Inhibitors

Anshul Gupta, Ganesh Mugundu, Pankaj B. Desai et al. · Drug Metabolism and Disposition · 2008 · 113 citations

A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma

Eduardo Méndez, Cristina P. Rodriguez, Michael Kao et al. · Clinical Cancer Research · 2018 · 106 citations · Full text

The pharmacokinetics of acyl, des-acyl, and total ghrelin in healthy human subjects

Jenny Tong, Nimita Dave, Ganesh Mugundu et al. · European Journal of Endocrinology · 2013 · 87 citations · Full text

A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer.

Neil H. Segal, Ajay K. Gopal, Shailender Bhatia et al. · Journal of Clinical Oncology · 2014 · 66 citations

, , +19

Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors

Naoko Takebe, Abdul Rafeh Naqash, Geraldine O’Sullivan Coyne et al. · Clinical Cancer Research · 2021 · 66 citations · Full text

1–5 of 32